IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1616
Examiner: PAK, JOHN D

In re PATENT APPLICATION of:

Applicant(s)	:	Lin ZHEN-MAN`	)
Application No.	:	10/469,063	) **AMENDMENT**
Filed	:	Aug 13, 2003	)
For	:	**Surface Treatment of SARS-Infected Lungs**	)

Commissioner of Patents
Washington, D.C. 20231
Dear Sir:

AMENDMENT on Jan. 02, 2006.

List of amendment and respond

1.	A statement for amendment	13 pages	
2.	ATTACHMENT A-- SUBSTITUTE SPECIFICATION	6 Pages	1 sets
	ATTACHMENT -- DRAWING CHANGES	7 Pages	
3.	**MARKED-UP** --SPECIFICATION	6 Pages	
4	ATTACHMENT B -- SUBSTITUTE CLAIMS	1 page	
5	**MARKED-UP** -- CLAIM CHANGES		
6	ATTACHMENT C – SUBSTITUTE ABSTRACT A	1 page	
7	**MARKED-UP--** ABSTRACT	1 page	
8	ATTACHMENT D—SUBSTITUTE drawing figure	6 page	
9	A CD to memory the data of PCT and amendment		

Attached Filed

a	A statement for amendment of PCT	3 Pages	
b	The Specification of PCT same the above 2. or in the CD	6 Pages	
c	Inventor was Protesting for WTO conference in HK.	1 page	
d	Inventor was warning to member countries of WTO/WHO	1 page	
e	Letter to Mr. Charles Jordan on 01/14/04 & 02/04/04	2 page	
f	Letter to Mr. Charles Jordan on Mar. 26, 2004	3 page	

Respectfully submitted,

Date

Jan. 02, 2006

Amendment by Applicant

PCT/SG03/00145 applicant:
Lin Zhen-man
Telephone: 65-63533647
Telefax: 65-62585636
Email: lzmyc@singnet.com.sg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1616
Examiner: PAK, JOHN D

In re PATENT APPLICATION of:

Applicant(s)	:	Lin ZHEN-MAN`	) About the
Application No.	:	10/469,063	) 37 CFR 1.121
			) **AMENDMENT**
Filed	:	Aug. 13, 2005	)
For	:	**Surface Treatment of SARS-Infected Lungs**	)

Commissioner of Patents
Alexandria, VA 22313-1450
Examiner,
PAK, JOHN D

Dear,

In response to the first Office Action of the date mailed on Sep.30, 2005, the period for reply to which has no been set to expire on the document of Office Action.

I, the applicant of above-identified application have a statement in here for this Office Action below.

Essentially, the US office must to admit applicant's amendment on PCT law! Not only the office has a Notice to admit that the Filing Date on Aug. 13, 2003, which total of 8 Claims and Publication on Dec.16, 2004, also the office's First Notice requested me to amend under 37 CFR 1.121; no problem, so I send a document list in which total 28 pages on Dec.14, 2004. The amendment document in which have send in a marked-up copy of the specification, Claims and SUBSTITUTE ABSTRACT are below:

1.	A statement for amendment	3 pages	
2.	ATTACHMENT A-- SUBSTITUTE SPECIFICATION	7 Pages	2 sets
3.	**MARKED-UP** --SPECIFICATION	6 Pages	
4	ATTACHMENT B -- SUBSTITUTE CLAIMS	1 page	2 sets
5	**MARKED-UP** -- CLAIM CHANGES		
6	ATTACHMENT C – SUBSTITUTE ABSTRACT	1 page	2 sets
7	Witness to the signed	1 page	

However, the First amendment was not all completely COMPLIANT for office, so the office made Second Notice for brings up a **new problem** send on Mar. 23, 2005. The Second amend document list is as stated below:

1	AMENDMENT for the Office Action of 03/23/05 (Statement)	4 Pages	
2	ATTACHMENT --PCT Original Claims	1 page	
3	**MARKED-UP** -- PCT CLAIMS CHANGES	1 page	
4	ATTACHMENT --PCT Substitute Claims	1 Page	
5	ATTACHMENT -- Marked-Up new CLAIMS CHANGES	1 page	
6	ATTACHMENT –new Substitute Claims	1 page	2sets

Attached Filed

a	A statement for amendment of PCT	3 Pages	
b	Substitute Specification	6 Pages	

Above the Second Amend Document under the confirmation of the officer that he received on 7/26/2005.

But the first section of Specification of Office Action Summary (page 3) which had a not correctness stated:

> 『 For example, applicant cannot send in a marked-up copy of the specification in one mailing, and then follow that up with a separate mailing of a clean copy of the specification. Hence, the substitute specification of 7/26/2005 is non-compliant because it did not include an accompanying marked-up copy of that substitute specification. 』

Evidently, the stated is wrong for my application; because I amended the specification on PCT and Dec.06, 2004. The office stated that my specification is not correct again:

> 『 …Also, a substitute specification MUST be filed with a statement by applicant that it CONTAINS NO NEW MATTER. 』

My statement for amending the specification in the list/Dec.06, 2004, why should the officer have a look? In the statement, it was very, very clear that the amendment CONTAINS NO NEW MATTER!

Dear Examiner, the office's First Notice requested me to amend the specification, abstract and claims, the First Notice which was directly pointing out that the abstract is the problem of section, the written language no any change, so it was not necessary an alone MARKED-UP document, because the Second Notice for amendment the **new problem of claims,** so office should not to oppose the specification and abstract amendment which filed on Dec.14, 2004 of First amendment.

Because of above the fact, I hope Mr. PAK, JOHN D can answer the letter that was sent on Oct.12, 2005 and made a phone call about it on Nov.28, 2005. But, there was no respond with the reference above, therefore, I still submit the third amend document on this Office Action and kindly ANEW AMEND the above-identified application which list as below:

1.	A statement for amendment	13 pages	
2.	ATTACHMENT A-- SUBSTITUTE SPECIFICATION	6 Pages	1 sets
	New Drawing Figure	6 Pages	
3.	**MARKED-UP** --SPECIFICATION	6 Pages	
4	ATTACHMENT B -- SUBSTITUTE CLAIMS	1 page	
5	**MARKED-UP** -- CLAIM CHANGES		
6	ATTACHMENT C – SUBSTITUTE ABSTRACT A	1 page	
7	ATTACHMENT C – SUBSTITUTE ABSTRACT B	1 page	
8	**MARKED-UP--** ABSTRACT	1 page	
9	ATTACHMENT D—SUBSTITUTE drawing figure	6 page	
10	A CD to memory the data of PCT and amendment		

Attached Filed

a	A statement for amendment of PCT	3 Pages	
b	Substitute Specification	6 Pages	
c	Inventor was Protesting for WTO conference in HK	1 page	
d	Inventor was warning to member countries of WTO/WHO	1 page	
e	Letter to Mr. Charles Jordan on Jan. 14, 2004	1 page	
f	Letter to Mr. Charles Jordan on Mar. 26, 2004	1 page	

IN THE amend **SPECIFICATION:**

Below to show is same the inventor basis on the Article 19/34 of PCT law to amended the specification on Dec.12, 2003. (To see the attached filed)

Simultaneously, applicant is set forth by the 37 CFR 1.121. for amending the specification again and affirmed that it CONTAINS NO NEW MATTER.

Below is the description of amended:

The amendment is further adds on the describe of PFC and insert the part of "Selection of PFC solvent" of specification, that is below:

【Per fluorine chemical compound (Per fluoro chemicals, PFC) in the innovation medicine application of this case is an important liquid-medium of oxygen for separate out single oxygen-atom. The member-type of PFC are **C(5-18)F(12-38),** the length of chain of member structure was shown at the number of C, the number of C decides was inner physical special quality, so the Boiling-Point was at **30℃-215℃.** That is to say, the Boiling-Point temperature with the number of C is in proportion. This application seeks to first recommend **C6F14 or C7F16,** its purpose for volatilizes as soon as possible then pouring into the lung after destroys the germs. But in actual practice of clinical option, more considerations will have to be taken into account, for instance, the level of ulcer by the germs influence and the density of single oxygen-atom and so on; however, then the other fluorine chemical compounds such as C5F9H3O while offering swim-dissociating for the liquid medium of single oxygen-atom, which must emphasize the density effect of single oxygen-atom Depletion Potential.】

Please see the part IV. (1) of the specification, above-mentioned additions had shown to add the base line. Obviously, the addition of the above-mentioned does not affect the novel of invention.

The amendment has further added a new figure to expose the art. of mixing PFC and ozone, according to order it was designate to be Fig.4, the described of Fig.4 insert for part IV. (3) and that under line shown in the **MARKED-UP** SUBSTIUTE SPECIFICATION, that below:

【The working process-method of mixing of PFC and ozone are shown in Fig.4. Fig.4-1 is shown the o zone supply；Fig.4-2 is shown the O3 Contriver；Fig.4-3 is shown PFC supply；Fig.4-4 is shown the passageway valve of liquid； Fig.4-5 is shown the pump of gas and liquid mixing；Fig.4-6 is the mix vessel； Fig.4-7 is the digital type tester of ozone density and have the export-ability to brake of the working of the mixing pump； Fig.4-8 is the controller of altitude of liquid and have the export-ability to the

working of the passageway valve of liquid.】

Obviously, the addition of the above-mentioned does not affect the novel of invention and that it CONTAINS NO any NEW MATTER; it is the responsibility of inventor to expose application-technology more distinctly. Therefore, the original Fig.4 according to order was designated to be Fig.5.

The " b. Surface treatment clinic scheme diagram" of part IV. (3) of the original copy was deleted and turn in accordance to order it was designated to be Fig.6, this kind of change is reasonable and necessary. Obviously, the changes to the above-mentioned do not affect the novel of invention or that it CONTAINS NO NEW MATTER.

The amendment included such as the correction on the usage of wrong words and so on, the accustomed to the amendment was underlined to show the correct ones; the deleted parts were represented by the square brackets and a substitute specification in compliance with the § 1.125(b)

IN THE amend **CLAIMS**

- Respond to the Claims of page 4, 5 and 6 of the examine overruled

The examine had a wrong state in page 4:

『 First, there cannot be two claim sets, Applicant should never submit two claim sets. That only leads to more non-compliant notices. In all future replies, applicant should submit only one claim set. All references to another, alternative claim set must be eliminated. 』

This first examine of Office Action has wrongly refuse the applicant's amend in PCT, but partially to censure in which had two claim sets, the examine was not careful under the Claims B which has a state for point out the total 8 claims of the Claims B which could be use for medicine and methods of medical treatment patent by patent-law of country, for instance US patent office and so on.

The examined overruled more wrong to criticize the total 5 claims of the Claims A in the second.

The examined overruled further to base on above wrong to conclusion in third. Obviously, the motive of examination was act biasness.

About the Content of Specification of Page 6-7:

1. The Content of Specification (a) was to cavil at the Title of the Invention, this title was brief but technically accurate and descriptive form invent.
2. The Content of Specification (b) was to cavil at the Cross-References to Related Applications from 37 CFR 1.78 and MPEP §201.11 which not any fact.
3. The Content of Specification (c) was to cavil at the Statement Regarding Federally Sponsored Research and Development; See MPEP §310. which not any fact too.
4. The Content of Specification (d) was to cavil for the Names Of The Parties To A Joint Research Agreement from See 37 CFR 1.71(g).

5. Applicant should be to offer a Compact Disc of specification respond required by the Content of Specification (e)

6. The Content of Specification (f) was to cavil for the Background of the Invention, the Background of the Invention of in specification of this application completed for the terms of MPEP §608.01(c). and under 37 CFR 1.97 and 37 CFR 1.98

7. The Content of Specification (g) was to cavil for the Brief Summary of the invention, in Part the Specification of this application was to a Brief Summary of the invention for completed the MPEP §608.01 as set forth in 37 CFR 1.73;

8. The Content of Specification (h) was to cavil for the Brief Description of the Drawing(s), the total 6 drawings with specification that amend in the PCT and officially of record in this application and still more publication on 12/16/2004. All the total 6 drawings were completed the MPEP § 608.01 and as set forth in 37 CFR 1.74.

9. The Content of Specification (i) was to cavil for the Detailed Description of the Invention, the part II.-IV of specification of this application was completed the MPEP §608.01(g) and as required in 37 CFR 1.71.

10. The Content of Specification (j) was to cavil for the Claim or Claims, the total 8 claims of this application was completed the 37 CFR 1.75 and MPEP 3 608.01(m) and 37 CFR 1.75 and MPEP 3 608.01(i)-(p).

11. The Content of Specification (k) was to cavil for the Abstract of the Disclosure, the ABSTRACT of Invention of this application was completed the MPEP 3 608.01(f) and MPEP3189303(e) etc.

12. The Content of Specification (l) was to cavil for the Sequence Listing, the sequence listing of this application was very, very plain and completed the 37 CFR 1.821-1.825 and MPEP 33 2421-2431.

The end of the Content of Specification of Page 8 in which was to divulged an astonishing purposed of discriminate against is below:

> 『The following is a quotation of the second paragraph of 35 U.S.C. 112:
>
> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
>
> Claims 1-4 are rejected as failing to define the invention in the manner required by 35 U.S.C. 112, second paragraph. 』

In the above-mentioned of Content of Specification, the examiner at all costs to made up out of whole cloth about his, but he did not know and damage the standard morality and demeanor of a patent leading powers.

The Claims of original is below:

1. The main characteristic of the "Surface Treatment of SARS–Infected Lungs" is to inject sterilizing liquid into the lung lobes.
2. The formal name for the medicine of sterilizing liquid is Per Fluoro Chemicals

(PFC) adding ozone forming a medicine.

3. Including any other lung diseases and SARS inflammation.
4. To add antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.

The inventor had basis on the Article 19/34 of PCT law to amendment the claims on Dec.12, 2003, the amendment claims are divide for two different editions, the Claim B which could be to fit the patent law of US patent office and officially of record in this application and still more publication on 12/16/2004.

The total 8 Claims which same the Claim B that was amend in PCT amendment abnormal submit is below again:

1. In the lungs infected disease field, wherein said the main characteristic treatment of the Surface Treatment of SARS–Infected Lungs is to inject sterilizing liquid into the lung lobes.
2. The Surface Treatment of SARS–Infected Lungs in claim1, the claim of patent medicine which formal name for the medicine of constituents sterilizing liquid is Fluoro Chemicals (PFCs) adding ozone forming [a medicine].
3. The Surface Treatment of SARS–Infected Lungs in claim 1, wherein said including any other lung diseases and SARS inflammation.
4. The Surface Treatment of SARS–Infected Lungs in claim 2, wherein said to add the substitutes such the antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.
5. In the claim 2, wherein said the liquid includes all liquids of fluorine element.
6. In the claim 2, wherein said includes any substitute liquid to mixing ozone or the single atom oxygen is decompose by other element.
7. The Surface Treatment of SARS–Infected Lungs in claim 7, wherein said to include a brand-new medical theory that is the Handling Effect Of Difference In Temperature" for cure cancer.
8. In the claim 7, wherein said to include a brand-new method of medical treatment of Frozen-Therapy for kill dead the cancer-cell.

The subject of Claims was annexed brand-new medical theories of claim 7 and methods of medical treatment of claim 8. They are stated in the specification and relate to the original claim 1, because, inventor has the power to add in the claims. Obviously, the changes to the claims of above-mentioned that do not affect the novel of invention or that it CONTAINS NO NEW MATTER and this amendments in reissue applications that it made in accordance with §1.173.

IN THE amend **ABSTRACT:**

In above the list of anew amend which a substitute abstract will be filed, the written words of abstract which no any change, from the three paragraph to synthesized the one paragraph only, I was in here statement that it CONTAINS NO NEW MATTER.

Respond the ABSTRACT of page 4.

In the document of this Office Action which section of Abstract has below critical notes:

『 Drawings are not permitted in the abstract, because the substitute abstracts of 2/9/2004 and 12/14/2004 were non-compliant, they were not entered. 』

This statement was wrongly, because the original Fig.4 according to order was designated to be Fig.5. The abstract picture is the original Fig.4 or the new number Fig.5 that it no any difference and CONTAINS NO NEW MATTER.

A very important question is, if the amend of 2/9/2004 were non-compliant, the office notice of 12/14/2004 must to send word the reason of refuse for the applicant, but the office notice of 12/14/2004 which no any to show and bring up other new master in there, this is hard to understand. The applicant was to implore admit by this amend which SUBSTITUTE ABSTRACT A or SUBSTITUTE ABSTRACT B that could be to choose by Examiner in this Office Action.

In the conclusion, the inventor had increased to state also all above-mentioned that such amendments might have on the description and the drawings.

A substitute specification (including the abstract and claims) is appended to this Amendment as Attachment A. A substitute abstract is appended to this Amendment as Attachment B. A substitute claims is appended to this Amendment as Attachment C. A substitute drawing-figure is appended to this Amendment as Attachment D.

The marked-up copy of amended which separately behind in the substitute specification, abstract, claims and drawing-figure.

The applicant again to declare which amending that it CONTAINS NO NEW MATTER.

For the foregoing reasons, it is respectfully submitted again that the application is now in condition for allowance.

To respond the art of anticipated by WO/03/082392

In the notice document of this examine, the WO 03/082392 is only to be relevant and rejected my Claims 1-4 under 35 U.S.C. 102(e)

In the first place, applicant was declaring in here, the applicant's claims were 1-8 that was amended basis Article 19/34 of PCT Law on Dec.12, 2003. The USA patent office must obey the PCT Law, if not, the USA patent office also to esteem yourself before the twice Notice requests me amendment under 37 CFR 1.121, the office's First Notice requests me for an amendment under 37 CFR 1.121, so I sent a document list consists of 28 pages on Dec.06, 2004. The amendment document in which included a marked-up copy of the SPECIFICATION, CLAIMS and SUBSTITUTE ABSTRACT. After that, the office made Second Notice only for bring up a **new problem** send on Mar. 23, 2005. The second notice of office in which no rejected my first amendment on Dec.06, 2004.

But the first section of Specification of Office Action Summary (page 3) which had a not correctly stated:

『 For example, applicant cannot send in a marked-up copy of the specification in one mailing, and then follow that up with a separate mailing of a clean copy of the specification. Hence, the substitute specification of 7/26/2005 is non-compliant because it did not include an accompanying marked-up copy of that substitute specification. 』

It was very obvious, if the Examiner still persistent to refuse to admit applicant's amendment, it will to cause a twister and discriminate against case of international.

At the same time, the WO 03/082392 and my application which to belong to in the different patent field and the claims of different subject.

At the page 11 of lines16 of the Specification of Office Action Summary, a comment to point out the Claims 1-4 are rejected under 35 U.S.C. 102(e) as being anticipated by WO 03/082392 and to show the concrete subject matter below:

	Question by **Examiner**	Respond by applicant
1	Page 9, lines 12	The correlation of ozone was no find;
2	Page 9, lines 23	That was merely to tell about that liberate free oxygen at the site of infection and these include (iv) ozone;
3.	Page 12, line 17 to page 13, line 2	That was merely to tell about that the oxygen-carrying substances consists of various synthetic chemical compounds which the Perfluorocarbons ("PFCs");
4.	Page 15, line 22	The correlation of ozone and PFCs were no find;
5.	Claim 1	The hyperbaric oxygen therapy is the subject of claim 1. The hyperbaric oxygen therapy not alike to the "Surface Treatment of SARS–Infected Lungs" therapy that is to inject sterilizing liquid into the lung lobes. The hyperbaric oxygen is not a sterilizing liquid, therefore, the hyperbaric oxygen therapy does not to cure the SARS and bird flu. So the claim 1 does not rejected the all claims of 10/469,063
6.	Claim 6	The claim 6 to use the PFCs for oxygenating agent; But the claims of 10/469,063 is use the PFCs for dissolvent of ozone. So the claim 6 does not rejected the all claims of 10/469,063
7.	Claim 10	The claim 10 is ancillary for the claim 9, but the claim 9 is to explain the claim 1, wherein said oxygenating agent generates oxygen by a chemical reaction. Obvious, the claim 10 was to shown use the ozone to generates oxygen, but the Claims and Specification of 10/469,063 which were to shown the nucleus of technology is in PFC liquid to mixing ozone for decompose the single atom oxygen. So the claim 10 does not rejected the all claims of 10/469,063
8.	Claim 11	Same claim 10, the claim 11 does not rejected the all claims of 10/469,063
9.	Claim 12	In the Claim 12, the patent field is shown at the intradermal, subcutaneous or intramucosal penetration.

		It was very obvious, the patent field of 10/469,063 is the Lungs. So the claim 12 does not rejected the all claims of 10/469,063
10	Claim 16	In the Claim 16, the patent field is shown at the layers of the dermis or the mucosa, but the patent field of 10/469,063 is the Lungs. So the claim 12 does not rejected the all claims of 10/469,063

To respond the Specification of WO/03/082392

In conjunction with an ant microbial agent, the formulation is for locally treating microbial infections such as viral infections (page 6, lines 12-13 and 19-21; claims 45, 50),

	Question by **Examiner**	Respond by applicant
1	Page 6, lines 12-13 and 19-21;	The subject of Page 6, lines 12-13 and 19-21 has increased the pO2 (dioxide of Phosphorus) in the oxygenating agent for the infected tissues (such as the cornea), this hyperbaric oxygen therapy not alike to the therapy of "Surface Treatment of SARS–Infected Lungs" and not alike field, so the narrate it does not reject all claims of 10/469,063
2	Claims 45	The hyperbaric oxygen therapy is the subject of claim 1, the claim 45 is to interpret for the claim 1, the hyperbaric oxygen is not a sterilizing liquid, therefore, the hyperbaric oxygen therapy does not cure the SARS and the bird flu in the lung, the lung is an unique patent field, so the claim 1 does not rejected the all claims of 10/469,063
3	Claims 50	The subject of claims 50 is the antimierobial agent being selected from the group consisting of AZT, Zovirax, and interferons, which were not alike to the application of 10/469,063, so the narrate it does not rejected the all claims of 10/469,063

Increasing the pO2 levels of an infected site can increased the efficacy of ant microbial agents and/or enhance the host's own defenses against the microbes that have invaded the site (sentence bridging pages 8 and 9).

4	Pages 8 and 9	The subject of oxygenating agents of the present invention can also be co-administered such as superoxide dysmutase ("SOD"), tocopherol, and ascorbic acid) which shown in Pages 8. The increased pO2 level for ischemic/hypoxic sites can be further related to the (A) oxygen-carrying agents, or (B) entrapped oxygen-generating agents which this all not to involve the therapy of Surface Treatment in lungs field for such the SARS–Infected in the Lungs, which this all not to involve the medicine of sterilizing liquid is Per Fluoro Chemicals (PFC) adding ozone forming a medicine.

The examiner had some commentary in the Page 11, line 2-8 of Specification of Office Action Summary which were below:

『 Treatment of viral infections of the respiratory tract is disclosed (page 17, lines

18-20). Infections of the lung are disclosed (sentence bridging pages 22 and 23). Treatment of viral infections is reiterated (claims 32-33; page 27, lines 7-10; page 30, table II), along with the use of antiviral co administration (page 26, line 4). Direct injection is disclosed (claims 28-29; page 22, lines 10-14; see also lines 15-19). A microbe that is "generally recognized as being difficult to treat" is treated (claims 33, 36). 』

However, the inventor has discovered that the examiner only search ***the interrelated fragmentary diction of such bacterial and viral pneumonias or other words of lungs,*** microbial infection and viral Pathogens etc. in the Page 17, lines 18-20, pages 22- 23; Claims 32-33; page 27, lines 7-10; page 30, table II, page 26, line 4, claims 28-29; page 22, lines 10-19 and claims 33, 36 of the above-mentioned paragraph, it was very to be clear about, the words of search meaningless for rejected the all claims 1-8 of 10/469,063, because the subject of WO 03/082392 is the **oxygenating agents** and the **hyperbaric oxygen therapy**, the WO 03/082392 and application of 10/469,063 are set two not alike subject and field, the inventor of WO 03/082392 does not knowledge and technological innovation or art in which to shown how to cure the pneumonias or the SARS or the bird flu and all this lung-infect is the Surface germs infect, opposite, the hyperbaric oxygen therapy only to help the Surface germs infect breed, but the therapy of "Surface Treatment of SARS–Infected Lungs" of application of 10/469,063 is immediate and effective, the medicine of sterilizing liquid is Per Fluoro Chemicals (PFC) adding ozone forming a medicine not alike to the claims of WO 03/082392, so **the interrelated words of search which should be meaningless not to rejected the all claims 1-8 of 10/469,063.**

In the Page 11, line 9-18 of Specification of Office Action Summary that had a call in question below:

『 As discussed earlier in this Office action, applicant's claims are interpreted as being directed to a composition. The cited reference explicitly discloses every composition feature required in applicant's claims. Use for SARS treatment is an intended use for a composition, and it is sufficient for examination of the composition invention that the same exact composition for similar utility is found in the prior art. A composition and its properties are inseparable, so the prior art composition must necessarily possess the properties now claimed by applicant, particularly since the prior art composition is known to be used to treat difficult to treat microbial infections such as difficult to treat viral infections. MPEP 2112, 2112.01. The claims are thereby anticipated. 』

In the claims of invention of 10/469,063 is a practical art, WHO and US CDC or China medicine circle whom no one to be at a loss what to do for the SARS and bird flu, WHY?

Because they could not understand the ecological environment type of infect-lung of the SARS, bird flu or any type flu were belong to the germs-infect of surface or outside the body, in the tenth paragraph of II.PREFACE of specification of 10/469,063 which had a very important science theory to set free the therapy of medical treatment:

『As there is a need to define air as an interface, so SARS infection is a kind of surface ulcerous infection. This is a new medical definition, which is likely to revolutionize lung treatment! 』

That is to say, using air as an interface definition, the bird flu, like SARS and other types of flu infections, is a superficial bacterial infection of the lungs. Such superficial bacterial infections can only be dealt with superficially. This can be said to be ***the law of the conversation***

of energy. And according to the law of the conversation of energy, any medicine which is to be ingested into the stomach or injected cannot be considered as a specific medicine, in the context of superficial bacterial infections, the claims 1-8 of 10/469,063 which composition and its properties are full of life.

In other words, the medicine circle whom could not understand the pathology, so they were not to find the specific remedy for cure the SARS and bird flu, they are very ignorant and also can not to differentiate what the virus-infect or the germs-infect, they are to popularized the ***Tarniflu*** is the specific remedy with vaccine for prophylaxis and treatment the bird flu in the near future!

To explain further, the ***Tarniflu*** relies on the absorption through the intestines and stomach in order to enter the blood stream to produce antibodies and to neutralize the viruses produced by the bacteria infection. Obviously, neutralization of the virus and killing of the bacteria are two totally different matters. While the vaccine can certainly bring about the production of antibodies in the blood, and neutralization of viruses is indeed the specialty of ***Tamiflu***, the effect of ***Tamiflu*** really depends on the type of the bacteria which produced the virus in the first place!

The Examiner should be not to act the illiteracy to reject the above law of infected-lung is a fact for change the medicine history of infect-lung! The PFC is the US 3M company's patent, the single atom were decomposed by Ozone for cure the germs in the chart of IV. 2. Part of specification of 10/469,063 that acknowledged by international society, the excellent character for dissolves Ozone in the PFC Fluids and dissolves Oxygen in the PFC Fluids use for lung that acknowledged by international society too, therefore, dissolves Ozone in the PFC Fluids to bring the singly O atom of disinfect element and which no any clinical questionable to hinder specific remedy for the bird flu, SARS and other types of flu.

Respond for the Content of Specification of Page 9:

1. Even though the Page 9(1) did not show what the patent rules to order the quotation marks are not permitted in a patent claim, the applicant was amend in this Office Action immediately;

2. The Examiner was to cavil for the Claim 2 merely discusses narrative the formal name of the Page 9(2) is wrong and ignorant, because the claim 2 was to disclose the prescription composition by Per Fluoro Chemicals (PFC) adding ozone;

3. The Examiner was to cavil for the Claim 3, 4 and 5 is to be unreasonable, because the claim 3, 4 and 5 were to amend and officially of record in this application and still more publication on 12/16/2004, now the total claims 8 were again to submit on this Office Action;

The Examiner was to advise the applicant that the claimed invention is directed to a method of treating SARS, the Examiner was very clear that this invention could cure all germs infection of the lungs in which includes the bird flu, phthisis and any type flu, if the claimed invention is directed to a method of treating SARS only, the applicant's benefits it will to reduce.

The Examiner was to be reminded that the applicant may be filed in the United States before the invention by the applicant for patent that shall not be entitled to a patent, the applicant was made to believe that in the <u>infect-lung field</u>, the methods of medical treatment of <u>Surface Treatment</u> for the SARS, bird flu and any type flu, <u>a brand-new medical theories that is the handling effect of difference in temperature for cure cancer and a brand-new methods of medical treatment of Frozen-Therapy for kill dead the cancer-cell</u> etc. it was to originate the medical

history, unusual, in which the prescription of PFC mix the Ozone is the specific remedy for bird flu in present only!

But, which country does admit the usage of bird flu? Unusual the WHO and US CDC, they are no also in unanimity to recommend the ***Tamiflu*** is effective in curing the bird flu?

The ***Tamiflu*** is not effective in curing the bird flu which was to refuted at the front side, please see the c and d of attach filed, I has protested against WTO conference in HK on Dec.13, 2005. Because, Hong Kong and China Government has requested all counties to assist in concealing my invention and this included the US government! Because the Jiang Ze-Min of the former china chairman was a politics hoodlum, he was to control the China Government to immoral and lawless for my invest in China and no to pleased for my complain since 1999. All this in the past, it no because I had to do a lawless actions for the causation. As the son of Jiang Ze-Min of the former china chairman called oneself and bribed Bush's brother and to make public on an official newspaper and website, no because the Jiang Ze-Min of the former china chairman was to tacitly agreed the US Government to sell the submarine of offensive weapons for Taiwan Government for conditions of exchanged to lead to the Bush Government in concert to impose sanction against for me.

The Examiner must to be clear about another case in US patent office that was immoral and unjustness for my patent application in 10/029,951 please to see the e and f of attach filed which two letters for Mr. Charles Jordan, the invent of 10/029,951 used for the Bush was to publicity at Airport Chicago on Sep. 27, 2005. This patent application of 10/029,951 was great value to rescue the US stock quotes in panic in the after 911, the president Bush was very glad to pass through an officer of US in HK consulate to made a call to promised that the patent application of 10/029,951 which could be rest assured application in US for me, but the promised by the US President it still a hollow words!

Today, the interfered it will same the above and the US patent office to lose the independent character it was very, very at apparent. I will to remind the officer, this patent application of PCT/SG03/00145 has now been submitted to the relevant patent authorities of 80% of WTO/WHO countries, any government's policy of medical treatment and to renew the textbook which can't do without this invent, therefore, please do not assist in concealing the truth, in insulting civilization, falsifying medical science, and deceiving the people of your country, thereby leaving a bad name in history.

If this examine Action still no impartial for me，the US patent office will to be notorious. The invent was to bring a case to court for the HK Chief Executive Donald TSANG Yam-kuen about the conceal and to tort for the immoral behavior now, but the US is to rule by law and great country, inventor will continuing to prevail on the Bush does not to form an alliance the Jiang Ze-Min of the former china chairman, because the devil that will stink to eternity in history, because to sell the submarine of offensive weapons for Taiwan Government that was to violate the Taiwan Relation and to conceal the medicine invent it will give more die for US people.

If the signature has an importance for this application, the office could be to consult from the record of PCT.

As this document of Office Action was mailed on 30th September 2005, the period for reply has not been set to expire on the document of Office Action, the applicant hope that the next Office Action is to be set to the expire date of total 6 months for the document of Office Action.

Conclusion

If the US office does not admit applicant's amendment on PCT law, the US officer must also to value herself, because the Second Notice of Office which has no reasons to reject the application and made Second Notice and brought up an new **problem** which was sent on Mar. 23, 2005.

The Specification of WO/03/082392 which no any medicine invent worthy to anticipated and belong to in the different patent field and the claims of different subject.

At the present day, it has no priority art that could be shown in this Office Action for rejecting this application of 10/469,063, the bird flu is menaced for the life of US people now, the ***Tamiflu*** is not effective in curing the bird flu and it is a falsehood and to play tricks for peoples of each country which was confirmed in this respond, the prescription of PFC mix Ozone invention in 10/469,063 is a specific remedy for the bird flu only, besides, the design and to sell of PFCO-Pharmacy- Machines it selfsame the inventor of 10/469,063, the address of website is the http://www.ycec.com/PFCO-Pharmacy-Machines.htm .

In the attached filed c, the examiner could see the fact that the Donald TSANG Yam-kuen of HK Chief Executive was to confirm murder inventor by an antenna radiation microwave, so the leader of Occident whom must to stopping provide help for conceal this invent for China and Hong Kong Government.

The inventor should be informed that the examiner another a fact, some conductor of country in purposed for the act of conceal to provide help for the Jiang Ze-Min of the former china chairman to exchanged beautiful woman and money, but they were must to announce another a lie for officer or people of himself country, especially for those official of such the sanitarian and patent office.

Therefore, the applicant requested the examiner of Office Action must show no partiality and not to massacre this invention and to ruin the civilized history of mankind.

Respectfully submitted,

Date: Jan. 02, 2005

applicant: Lin Zhen-man

Telephone: 65-63533647
Telefax: 65-62585636
Email: lzmyc@singnet.com.sg

To
U.S. Patent and Trademark Office
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

(SUBSTITUTE SPECIFICATION)

Surface Treatment of SARS-Infected Lungs

I. Background of the invention

Since February 2003 years, SARS infection has wreaks havoc in China, Hong Kong and many other countries in the world. Its effects had send repercussion throughout the entire international society. The death rate has been high and the Chinese and western medical social were quite helpless about this. So China, Taiwan, Hong Kong, Singapore and Canada etc. were listed on travel warning district by World Health Organization and pecuniary loss surmount thousand a hundred million, Mankind is faced with death threat.

Knowing how to treat the SARS virus infection had became the top most urgent matter in the Southeast Asia. During this urgent and difficult period of time, the inventors had come up with an innovative medical scheme to save lives; the newest of medical scheme is "Surface Treatment of SARS-Infected Lungs". Due to the urgency of saving lives, the draft was fax to the Hong Kong chief executive and Chinese leader on 15 May 2003. The English version was also forwarded to "WHO-Padey", "WHO-Liden" by Mey-Verme, Mrs Cnia (WDC) and the leaders who were holding the Geneva meeting on 20 May 2003.

II. PREFACE

About the functions of the lungs.

The lungs mainly serve to redistribute the blood from the right ventricle via the lung artery to various lung sub-arteries and capillary vessels in the alveoli, thus achieving gas exchange introducing oxygen and releasing carbon dioxide. Then the blood returns from the lung veins to the left atrium and mixed at a certain proportion in the right ventricle. That is the big circulation of oxygen-containing blood in the arteries providing energy for the body! (Fig. 1.)

Here the medium for gas exchange is not special, just like pumping the air to the bottom of a fish jar to produce bubbles and the oxygen enters the water by rubbing against the external spherical surfaces of the rising bubbles. Our alveoli work like the bubbles in the fish jar and have a large surface area for air contact. The contact area of the dense alveolus tissues in the lungs is up to 70 m^2! Tiny blood vessels are spread over the surfaces of these tissues to complete "gas exchange" or, in other words, pulmonary ventilation, via distribution through the blood, interstitial layer and cells. That is the basic idea of the lungs according to modern medicine.

On the medical history, sort of Lung diseases have been numerous. Tuberculosis used to be an infectious disease difficult to cure. However, it can be cured 100% thanks to the discovery of multiple antibiotics. Infant pneumonia is also a common disease, not to speak of pneumococcus. This article describes how to treat SARS.

First, treatment by the traditional Chinese medicine. This method mainly relies on absorption function of the intestines and stomach, which impedes the development of the traditional Chinese medicine. Traditional Chinese prescriptions only help the intestines and stomach to share the burden of the liver, thereby improving only our immunity.

However, the prevailing SARS cures at present are based on Western medicine. The Chinese mainland advocates such antibiotics like tetracycline and erythromycin while Hong Kong regards ribavirin and steroid as effective SARS-containing medicines, but in Canada, which had used Ribavirin for a long time, has now stopped using it because it may have serious side effects.

However, no matter how to, the antibiotics is being absorbed by the intestines and stomach or injected via the veins, they cannot change the subject of the method of transporting anti-bacterium factors in the blood. We call this method blood therapy. Because, many elements in the anti-bacterium factors cannot be absorbed by the intestines and stomach, so the Western medicine takes the lead by this therapy.

That is why the medical circles are focusing on how to improve the efficiency of the "anti-bacterium factors".

But, as shown in Fig.2, if the injection point is found in the arteries of the lungs, then the "blood therapy"

may become much more effective, as proven by the noticeable flow ratio of the artery and lung circulation. SARS-containing clinical practice is thus more effective. However, we want to point out that the efficiency direction of the "anti-bacterium blood therapy" of SARS is wrong.

As there is a need to define air as an interface, so SARS infection is a kind of surface ulcerous infection. This is a new medical definition, which is likely to revolutionize lung treatment! Therefore we use a familiar industrial term "surface treatment" and to include a technique of supersonic treatment. This is like applying purple liquid medicine to the ulcerous skin which is much more effective than "blood therapy" using any antibiotic.

Up to this point, we can optimistically predict that once the "surface treatment" technique which depends on various antibiotics recommended has found clinic applications, then a SARS patients need only to go to the hospital to have their lungs washed, and SARS will no longer be fatal. At the same time it can also be effective for other pneumonia diseases.

Let's learn something about the physical properties of SARS before dealing with the subject matter of this article—SARS treatment:

1. Fig. 3 is downloaded from the Internet. SARS virus is smaller than 50 nanometers. SARS virus has numerous crown-like developments, making it absorptive. Overcoming such absorption is significant for the "surface treatment" technique recommended in this article. When we contract bacterium-induced faucitis, we just wet our throat with brine and the pain immediately subsides, because some bacteria are "washed away" by brine, as proven by observing under an electronic endoscope. This traditional inflammation relief method through brine is well-known to all. Inspired by this idea, I think such a simple method can also prevent SARS virus from entering the lungs through the mouth and throat.

2. Super-small and super-light virus is visible only through an electronic microscope and the 75-nm N95 standard respirators we use cannot keep out SARS virus, so SARS virus spreads by means of the tiny water droplets and dust particles in the air. In view of that, we can work out a series of effective preventive measures like the "surface treatment" method recommended in this article.

III. Five lung "surface treatment" methods

1. Antibiotic gasification and absorption;
2. Massage and sternutation;
3. Taking out and sterilizing lung lobes;
4. Local quick freezing for sterilizing of lung lobes;
5. Injecting sterilizer into lung lobes.

Discussion 1

The method of antibiotic gasification and absorption is not new. This method is effective at the early stage of infection and may serve as a preventive measure before and after medical operation. This method presupposes that the antibiotic in question must be dissolvable in 37℃ water.

Discussion 2

The method of massage and sternutation is more suitably called physical therapy. It works like this: pressing the alveoli by applying force on the lungs and detaching the virus from the cell wall of the alveoli. Facing the nose toward the sun may help to induce sternutation, which is recommendable at the early stage of infection or as a preventive measure. Therefore sunlight sternutation device will be popular on the market. Sternutation is the best exercise for the chest and lungs, and sneezing three times a day is good for senior citizens. The benefits of such an exercise are hardly known but it is a good piece of news for people with weak lungs. This method is just preventive but not effective in detaching the highly absorptive SARS virus.

Discussion 3

Taking out and sterilizing lung lobes is not just a dream. It involves the invention and clinical application of external blood oxygen adding device. This method includes liquid medicine submersion and temperature difference treatment, the latter being the latest medical concept not only suitable for lung patients but also for

cancer patients and others. Further exploration of this method may help to replace antibiotic blood therapy with this method:

a. External liquid medicine submersion is more flexible that internal liquid medicine submersion. There are a few or no Liquid medicines that do not damage alveolus tissues. However, an effective liquid medicine for lung lobe submersion will be more effective and attractive if combined with supersonic wave.
b. What is temperature difference treatment? The organs and virus under treatment have difference physiological temperature curves. Temperature difference effect is achieved by selecting a temperature point which is fatal to viruses but from which the organs treated can revive. It is not important whether this method is recorded in medical literature, but the method proves simple, the essential point is the revival rate of the organ under treatment. This is therefore a highly recommended method.

Discussion 4

Local quick freezing and sterilizing of lung lobes is also based on temperature differences but technically it is an improvement from the above three discussions. Taking out lung lobes without cutting off arteries and veins may minimize the damage to the organ and inter-organ contact, making this method practical. While it is difficult to carry out on Lungs, it is feasible for "semi-detached organs" like. The root of the problem is that the quick-freezing equipment involved is not as simple as an ammonia cyclic refrigerator. The clinic freezing device must work in contact mode and is capable of lowering the temperature of an organ of about 1 kg to -30-50℃ within 5 ~ 10 seconds. Many medical fields are gone up and breakthroughs will rely on this kind of technical accomplishment that is made in accordance to the trade circle of science and technology requirement.

Discussion 5

Injecting sterilizer into lung lobes is the subject matter of surface treatment technique of this article. I do not specialize in medicine but just a little medically minded. Inspired by the idea of relieving oral and throat inflammation with brine solution, I managed to find some suitable solvent and sterilizer, but it has to undergo clinical test. But I'm sure that so long as some qualified chemist proposes and there is an adequate range of solvents and sterilizers, SARS will be overcome!

IV. O1 Therapy for "surface treatment" of the lungs

The sterilizing liquid injected into lung lobes is the surface treatment liquid for O1 therapy of the lungs. The formal name for this liquid is Per fluoro chemicals (PFC) and the sterilizer is ozone.

This method of introducing supersonic wave with sterilizing liquid may make SARS virus less absorptive and quickly clear viruses in the lungs. This new and practical therapy works like bombing the SARS virus with smart cruise missiles. The missile is single oxygen (O1) separated from ozone, hence "O1 Therapy"!

The effect of the regular antibiotic therapy currently used is limited in that this therapy entails blood exchange, and it is also limited by blood density. For example 50nm-minus SARS virus is hidden in the middle layer that is inaccessible via the capillary vessels, so the mortality rate of this "blood therapy" is still over 10%. The "blood therapy" of Western medicine has reached its maximum potential. On the contrary, "O1 therapy" is highly effective and is likely to reduce the death rate to zero:

1. Selection of PFE solvent;
2. Properties of ozone sterilizer;
3. Mixing of PFC and ozone;
4. Lung "surface treatment" design flow;
5. Test with animal lung;
6. Special of operating table.

1. Selection of PFC solvent

PFC comes to our mind when we select a liquid medium for cleaning alveoli. Clinical cases are available for PFC breathing technique. We can rely completely on such an effective sterilizer or antibiotic to kill SARS virus. PFC has the characteristics:

1. No color, taste or smell, not poisonous;
2. Low surface tensile strength, not dissolvable in water or fat;
3. High dissolving coefficient for oxygen and carbon dioxide, high density and low solubility, higher dissolving coefficient for ozone;
4. Volatile under indoor temperature and body temperature, does not changeable into other matter via catabolism;

Per fluorine chemical compound (Per fluoro chemicals, PFC) in the innovation medicine application of this case is an important liquid-medium of oxygen for separate out single oxygen-atom. The member-type of PFC are **C(5-18)F(12-38),** the length of chain of member structure was shown at the number of C, the number of C decides was inner physical special quality, so the Boiling-Point was at **30℃-215℃.** That is to say, the Boiling-Point temperature with the number of C is in proportion. This application seeks to first recommend **C6F14 or C7F16,** its purpose for volatilizes as soon as possible then pouring into the lung after destroys the germs. But in actual practice of clinical option, more considerations will have to be taken into account, for instance, the level of ulcer by the germs influence and the density of single oxygen-atom and so on; however, then the other fluorine chemical compounds such as **C5F9H3O** while offering swim-dissociating for the liquid medium of single oxygen-atom, which must emphasize the density effect of single oxygen-atom Depletion Potential.

With the above features, PFC qualifies as a lung surface treatment liquid. It has a dynamic function. On the one hand, oxygen can pass through it to achieve constant gas exchange in the lungs, and on the other hand, the liquid PFC can permeate any alveoli, so that the O1 element in PFC can freely trace SARS virus. The volatility of PFC ensures that no sequela will appear. What is more, PFC can also clean the lungs of damaged cells, cell fragments resulting from inflammation, and SARS virus residuals.

2. Characteristics of ozone sterilizer

1. The molecule formula of ozone is O3, which is an allotrope of high-energy oxygen and is dissolvable in water and various liquid chemicals;
2. Low-density ozone is colorless and smells like a special grass. It is blue at high temperature and its density is 1.5 times that of air;
3. Ozone sterilizes by releasing single oxygen atom to oxidize and damage the cell of the virus, leaving pure O2, which is beneficial to the lungs;
4. Ozone dissolved in water sterilizes more forcibly and quickly, and it is dissolvable in liquid PFC;
5. When the density of ozone exceeds a certain limit, its sterilizing function is just a matter of seconds;

Therefore, ozone is a good choice as an alveoli sterilizer. The following figures are cited from world-recognized experiment documentation for ozone sterilizing.

	Density	Time	Types of viruses and pathogens	Sterilizing efficiency
Ozone sterilizing	10mg/m3	20 mins	Type-B hepatitis surface antigen (HbsAg)	99.99%
	0.5ppm	5 mins	Type-A flu virus	99%
	0.13mg/L	30 seconds	Poliomyelitis virus type I (PVI)	100%
	40μg/L	20 seconds	Coliphage ms2	98%
	0.25mg/L	1 minute	SA-H and human-wheel virus type 2	99.60%
	*** 12.6mg/L**	**4 minutes**	**Coronaviridae**	**100%**
	4mg/L	3 minutes	HIV	100%
	8mg/m3	10 minutes	Mycoplasma, Chlamydia, and other pathogens	99.85%

- Red indicates every liter of lung surface treatment solution contains 12.6mg ozone, which may serves as a reference when we consider the test dosage of ozone.

3. Mixing of PFC and ozone

The working process-method of mixing the PFC and ozone are shown in Fig.4. Fig.4-1 shows the ozone supply；Fig.4-2 shows the O3 Contriver；Fig.4-3 shows the PFC supply；Fig.4-4 shows the passageway valve of liquid； Fig.4-5 shows the pump of gas and liquid mixing；Fig.4-6 is the mix vessel； Fig.4-7 is the digital type tester of ozone density which has the export-ability to brake of the working of the mixing pump；Fig.4-8 is the controller of altitude of liquid and have the export-ability to the working of the passageway valve of liquid.

4. Lung "surface treatment" flow

The treatment flow takes the treatment for example of the right lung, while reserving the breath of the left lung for the time being. The final purpose is to treat both lungs at the same time. Process 3 can only be used only after process 4. Test it with animal lung, before applying it on human. It must be noted that the test with animal lung is intended to prove that it applies to process 3, the human body treatment. The advantage of the reverse sequence is time saving.

a. **Surface treatment clinic (must be professional anesthetist except for bio-chemical test of body energy):** (Fig. 5)

b. **Surface treatment clinic scheme diagram:** (Fig. 6)

5. Test with animal lung

Test with animal lung includes two stages: test with one lung of the baby pig and test with both lungs. This process simulates process 3, as specified below:

a. Inject pure PFC into three without virus influence of baby pig:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									

b. Inject 12.6mg/L PFC into three virus-free pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

c. Inject 25.2mg/L PFC into three virus-free pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

d. Inject 12.6mg/L PFC into three infected of baby pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

Note 1. The above a-c tests are intended to test whether PEC solvent with or without ozone has bad effect on the lungs. In test c, the density of ozone can be further increased until a reliable pig lung reaction curve, which may serve as a reference for chemists for preparing prescriptions for human treatment.

Note 2. Test d is intended for SARS inflammation, needing an infected pig. Tests with difference densities can be worked out by analogy, but the baby pig under the test is much more resistant to diseases than man. Usually, after 1-3 medicine reaction tests, similar results can be obtained in the tests with various dosages and can be observed under a microscope, and the bio-chemical lab can work out a guided report for the chemists in a short time. The test planning is for your reference only.

6. Important points in designing the operation table

The operation table should be designed such that it can turn horizontally so that the patient on the table can turn left or right with an angle of at least 45 degrees to facilitate the treatment of the left and right lungs.

V. Conclusion

From the viewpoints mentioned above, the ability of ozone to kill virus was recognized worldwide, ozone application in the PFC solvent was confirmed by 1 of remark of the famous production businesses, the PFC solvent used in the lung had also supported by 2-8 of remark of medical document. Therefore, combining the PFC solution and ozone together will attack the SARS virus in no time. The[method] medicine scheme will definitely treat the SARS virus infection and there will be no side effect at all. This invention will save many lives and change medical-history for lung Infection-Disease.

The handling effect of difference in temperature of invention's theory can also kill dead cancer-cell under completely no side effect, the effect of medical treatment cannot compared with Electrotherapy and Chemotherapy, hence the invention bring Gospel for cancer patient, it was so far the brand-new medical concept and brand-new medical method of "Frozen-Therapy".

-end-

Remark of Paper/WebPages:

1. http://cms.3m.com/cms/US/en/2-68/iFcFiFM/view.jhtml
2. http://www.vghtpe.gov.tw/~clinmed/ (Taiwan 89 年 12 月期) [Chinese]

Paper in international journals:

3. Jeng MJ, Kou YR*, Sheu CC, Hwang B. Effects of Exogenous Surfactant Supplementation and Partial Liquid Ventilation on Acute Lung Injury Induced by Wood Smoke Inhalation in Newborn Piglets. Crit Care Med 2003; 31:1166-1174
4. Jeng MJ*, Yang SS, Wolfson MR, Shaffer TH. Perfluorochemical (PFC) Combinations for Acute Lung Injury: An in Vitro and in Vivo Study in Juvenile Rabbits. Pediatr Res 2003;53:81-88.
5. Jeng MJ*, Oliver R, Wolfson MR, Shaffer TH. Partial liquid ventilation: effect of initial dose and redosing strategy in acute lung injury. Pediatr Crit Care Med 2002;3:163-171.
6. Jeng MJ*, Kou YR, Sheu CC, Hwang B. Effects of partial liquid ventilation with FC-77 on acute lung injury in newborn piglets. Pediatr Pulmonol 2002; 33:12-21.
7. Jeng MJ*, Trevisanuto D, Weis CM, Fox WW, Wolfson MR, Shaffer TH. The role of ventilation strategy on Perfluorochemical (PFC) evaporation from the lungs. J Appl Physiol 2001; 90: 1365-1372.
8. Trevisanuto D, Jeng MJ*, Weis CM, Fox WW, Wolfson MR, Shaffer TH. Positive end-expiratory pressure modulates perfluorochemical evaporation from the lungs. Biol Neonate 2003;84:53-58.

MARKED-UP SUBSTIUTE SPECIFICATION

Surface Treatment of SARS-Infected Lungs

I. Background of the invention

Since February 2003 years, SARS infection has wreaks havoc in China, Hong Kong and many other countries in the world. Its effects had send repercussion throughout the entire international society. The death rate has been high and the Chinese and western medical social were quite helpless about this. So China, Taiwan , Hong Kong, Singapore and Canada etc. were listed on travel warning district by World Health Organization and pecuniary loss surmount thousand a hundred million, Mankind is faced with death threat.

Knowing how to treat the SARS virus infection had became the top most urgent matter in the Southeast Asia. During this urgent and difficult period of time, the inventors had come up with an innovative medical scheme to save lives; the newest of medical scheme is "Surface Treatment of SARS-Infected Lungs". Due to the urgency of saving lives, the draft was fax to the Hong Kong chief executive and Chinese leader on 15 May 2003. The English version was also forwarded to "WHO-Padey", "WHO-Liden" by Mey-Verme, Mrs Cnia (WDC) and the leaders who were holding the Geneva meeting on 20 May 2003.

II. PREFACE

About the functions of the lungs.

The lungs mainly serve to redistribute the blood from the right ventricle via the lung artery to various lung sub-arteries and capillary vessels in the alveoli, thus achieving gas exchange introducing oxygen and releasing carbon dioxide. Then the blood returns from the lung veins to the left atrium and mixed at a certain proportion in the right ventricle. That is the big circulation of oxygen-containing blood in the arteries providing energy for the body! (Fig. 1.)

Here the medium for gas exchange is not special, just like pumping the air to the bottom of a fish jar to produce bubbles and the oxygen enters the water by rubbing against the external spherical surfaces of the rising bubbles. Our alveoli work like the bubbles in the fish jar and have a large surface area for air contact. The contact area of the dense alveolus tissues in the lungs is up to 70 m^2! Tiny blood vessels are spread over the surfaces of these tissues to complete "gas exchange" or, in other words, pulmonary ventilation, via distribution through the blood, interstitial layer and cells. That is the basic idea of the lungs according to modern medicine.

On the medical history, sort of Lung diseases have been numerous. Tuberculosis used to be an infectious disease difficult to cure. However, it can be cured 100% thanks to the discovery of multiple antibiotics. Infant pneumonia is also a common disease, not to speak of pneumococcus. This article describes how to treat SARS.

First, treatment by the traditional Chinese medicine. This method mainly relies on absorption function of the intestines and stomach, which impedes the development of the traditional Chinese medicine. Traditional Chinese prescriptions only help the intestines and stomach to share the burden of the liver, thereby improving only our immunity.

However, the prevailing SARS cures at present are based on Western medicine. The Chinese mainland advocates such antibiotics like tetracycline and erythromycin while Hong Kong regards ribavirin and steroid as effective SARS-containing medicines, but in Canada, which had used Ribavirin for a long time, has now stopped using it because it may have serious side effects.

However, no matter how to, the antibiotics is being absorbed by the intestines and stomach or injected via the veins, they cannot change the subject of the method of transporting anti-bacterium factors in the blood. We call this method blood therapy. Because, many elements in the anti-bacterium factors cannot be absorbed by the intestines and stomach, so the Western medicine takes the lead by this therapy.

That is why the medical circles are focusing on how to improve the efficiency of the "anti-bacterium factors".

But, as shown in Fig.2, if the injection point is found in the arteries of the lungs, then the "blood therapy" may become much more effective, as proven by the noticeable flow ratio of the artery and lung circulation.

SARS-containing clinical practice is thus more effective. However, we want to point out that the efficiency direction of the "anti-bacterium blood therapy" of SARS is wrong.

As there is a need to define air as an interface, so SARS infection is a kind of surface ulcerous infection. This is a new medical definition, which is likely to revolutionize lung treatment! Therefore we use a familiar industrial term "surface treatment" and to include a technique of supersonic treatment. This is like applying purple liquid medicine to the ulcerous skin which is much more effective than "blood therapy" using any antibiotic.

Up to this point, we can optimistically predict that once the "surface treatment" technique which depends on various antibiotics recommended has found clinic applications, then a SARS patients need only to go to the hospital to have their lungs washed, and SARS will no longer be fatal. At the same time it can also be effective for other pneumonia diseases.

Let's learn something about the physical properties of SARS before dealing with the subject matter of this article—SARS treatment:

1. Fig. 3 is downloaded from the Internet. SARS virus is smaller than 50 nanometers. SARS virus has numerous crown-like developments, making it absorptive. Overcoming such absorption is significant for the "surface treatment" technique recommended in this article. When we contract bacterium-induced faucitis, we just wet our throat with brine and the pain immediately subsides, because some bacteria are "washed away" by brine, as proven by observing under an electronic endoscope. This traditional inflammation relief method through brine is well-known to all. Inspired by this idea, I think such a simple method can also prevent SARS virus from entering the lungs through the mouth and throat.

2. Super-small and super-light virus is visible only through an electronic microscope and the 75-nm N95 standard respirators we use cannot keep out SARS virus, so SARS virus spreads by means of the tiny water droplets and dust particles in the air. In view of that, we can work out a series of effective preventive measures like the "surface treatment" method recommended in this article.

III. Five lung "surface treatment" methods

1. Antibiotic gasification and absorption;
2. Massage and sternutation;
3. Taking out and sterilizing lung lobes;
4. Local quick freezing for sterilizing of lung lobes;
5. Injecting sterilizer into lung lobes.

Discussion 1

The method of antibiotic gasification and absorption is not new. This method is effective at the early stage of infection and may serve as a preventive measure before and after medical operation. This method presupposes that the antibiotic in question must be dissolvable in 37℃ water.

Discussion 2

The method of massage and sternutation is more suitably called physical therapy. It works like this: pressing the alveoli by applying force on the lungs and detaching the virus from the cell wall of the alveoli. Facing the nose toward the sun may help to induce sternutation, which is recommendable at the early stage of infection or as a preventive measure. Therefore sunlight sternutation device will be popular on the market. Sternutation is the best exercise for the chest and lungs, and sneezing three times a day is good for senior citizens. The benefits of such an exercise are hardly known but it is a good piece of news for people with weak lungs. This method is just preventive but not effective in detaching the highly absorptive SARS virus.

Discussion 3

Taking out and sterilizing lung lobes is not just a dream. It involves the invention and clinical application of external blood oxygen adding device. This method includes liquid medicine submersion and temperature difference treatment, the latter being the latest medical concept not only suitable for lung patients but also for cancer patients and others. Further exploration of this method may help to replace antibiotic blood therapy

with this method:

a. External liquid medicine submersion is more flexible that internal liquid medicine submersion. There are a few or no Liquid medicines that do not damage alveolus tissues. However, an effective liquid medicine for lung lobe submersion will be more effective and attractive if combined with supersonic wave.
b. What is temperature difference treatment? The organs and virus under treatment have difference physiological temperature curves. Temperature difference effect is achieved by selecting a temperature point which is fatal to viruses but from which the organs treated can revive. It is not important whether this method is recorded in medical literature, but the method proves simple, the essential point is the revival rate of the organ under treatment. This is therefore a highly recommended method.

Discussion 4

Local quick freezing and sterilizing of lung lobes is also based on temperature differences but technically it is an improvement from the above three discussions. Taking out lung lobes without cutting off arteries and veins may minimize the damage to the organ and inter-organ contact, making this method practical. While it is difficult to carry out on Lungs, it is feasible for "semi-detached organs" like. The root of the problem is that the quick-freezing equipment involved is not as simple as an ammonia cyclic refrigerator. The clinic freezing device must work in contact mode and is capable of lowering the temperature of an organ of about 1 kg to -30-50℃ within 5 ~ 10 seconds. Many medical fields are gone up and breakthroughs will rely on this kind of technical accomplishment that is made in accordance to the trade circle of science and technology requirement.

Discussion 5

Injecting sterilizer into lung lobes is the subject matter of surface treatment technique of this article. I do not specialize in medicine but just a little medically minded. Inspired by the idea of relieving oral and throat inflammation with brine solution, I managed to find some suitable solvent and sterilizer, but it has to undergo clinical test. But I'm sure that so long as some qualified chemist proposes and there is an adequate range of solvents and sterilizers, SARS will be overcome!

[IIII] IV. O1 Therapy for "surface treatment" of the lungs

The sterilizing liquid injected into lung lobes is the surface treatment liquid for O1 therapy of the lungs. The formal name for this liquid is Per fluoro chemicals (PFC) and the sterilizer is ozone.

This method of introducing supersonic wave with sterilizing liquid may make SARS virus less absorptive and quickly clear viruses in the lungs. This new and practical therapy works like bombing the SARS virus with smart cruise missiles. The missile is single oxygen (O1) separated from ozone, hence "O1 Therapy"!

The effect of the regular antibiotic therapy currently used is limited in that this therapy entails blood exchange, and it is also limited by blood density. For example 50nm-minus SARS virus is hidden in the middle layer that is inaccessible via the capillary vessels, so the mortality rate of this "blood therapy" is still over 10%. The "blood therapy" of Western medicine has reached its maximum potential. On the contrary, "O1 therapy" is highly effective and is likely to reduce the death rate to zero:

1. Selection of PFE solvent;
2. Properties of ozone sterilizer;
3. Mixing of PFC and ozone;
4. Lung "surface treatment" design flow;
5. Test with animal lung;
6. Special of operating table.

1. Selection of [PFF] PFC solvent

PFC comes to our mind when we select a liquid medium for cleaning alveoli. Clinical cases are available for PFC breathing technique. We can rely completely on such an effective sterilizer or antibiotic to kill SARS virus. PFC has the characteristics:

1. No color, taste or smell, not poisonous;
2. Low surface tensile strength, not dissolvable in water or fat;
3. High dissolving coefficient for oxygen and carbon dioxide, high density and low solubility, higher dissolving coefficient for ozone;
4. Volatile under indoor temperature and body temperature, does not changeable into other matter via catabolism;

Per fluorine chemical compound (Per fluoro chemicals, PFC) in the innovation medicine application of this case is an important liquid-medium of oxygen for separate out single oxygen-atom. The member-type of PFC are **C(5-18)F(12-38),** the length of chain of member structure was shown at the number of C, the number of C decides was inner physical special quality, so the Boiling-Point was at **30℃-215℃.** That is to say, the Boiling-Point temperature with the number of C is in proportion. This application seeks to first recommend **C6F14 or C7F16,** its purpose for volatilizes as soon as possible then pouring into the lung after destroys the germs. But in actual practice of clinical option, more considerations will have to be taken into account, for instance, the level of ulcer by the germs influence and the density of single oxygen-atom and so on; however, then the other fluorine chemical compounds such as **C5F9H3O** while offering swim-dissociating for the liquid medium of single oxygen-atom, which must emphasize the density effect of single oxygen-atom Depletion Potential.

With the above features, PFC qualifies as a lung surface treatment liquid. It has a dynamic function. On the one hand, oxygen can pass through it to achieve constant gas exchange in the lungs, and on the other hand, the liquid PFC can permeate any alveoli, so that the O1 element in PFC can freely trace SARS virus. The volatility of PFC ensures that no sequela will appear. What is more, PFC can also clean the lungs of damaged cells, cell fragments resulting from inflammation, and SARS virus residuals.

2. Characteristics of ozone sterilizer

1. The molecule formula of ozone is O3, which is an allotrope of high-energy oxygen and is dissolvable in water and various liquid chemicals;
2. Low-density ozone is colorless and smells like a special grass. It is blue at high temperature and its density is 1.5 times that of air;
3. Ozone sterilizes by releasing single oxygen atom to oxidize and damage the cell of the virus, leaving pure O2, which is beneficial to the lungs;
4. Ozone dissolved in water sterilizes more forcibly and quickly, and it is dissolvable in liquid PFC;
5. When the density of ozone exceeds a certain limit, its sterilizing function is just a matter of seconds;

Therefore, ozone is a good choice as an alveoli sterilizer. The following figures are cited from world-recognized experiment documentation for ozone sterilizing.

	Density	Time	Types of viruses and pathogens	Sterilizing efficiency
Ozone sterilizing	10mg/m3	20 mins	Type-B hepatitis surface antigen (HbsAg)	99.99%
	0.5ppm	5 mins	Type-A flu virus	99%
	0.13mg/L	30 seconds	Poliomyelitis virus type I (PVI)	100%
	40μg/L	20 seconds	Coliphage ms2	98%
	0.25mg/L	1 minute	SA-H and human-wheel virus type 2	99.60%
	*** 12.6mg/L**	**4 minutes**	**Coronaviridae**	**100%**
	4mg/L	3 minutes	HIV	100%
	8mg/m3	10 minutes	Mycoplasma, Chlamydia, and other pathogens	99.85%

- Red indicates every liter of lung surface treatment solution contains 12.6mg ozone, which may serves as a reference when we consider the test dosage of ozone.

3. Mixing of PFC and ozone

The working process-method of mixing the PFC and ozone are shown in Fig.4. Fig.4-1 shows the ozone supply；Fig.4-2 shows the O3 Contriver；Fig.4-3 shows the PFC supply；Fig.4-4 shows the passageway valve of liquid；Fig.4-5 shows the pump of gas and liquid mixing；Fig.4-6 is the mix vessel； Fig.4-7 is the digital type tester of ozone density which has the export-ability to brake of the working of the mixing pump；Fig.4-8 is the controller of altitude of liquid and have the export-ability to the working of the passageway valve of liquid.

[3]4. Lung "surface treatment" flow

The treatment flow takes the treatment for example of the right lung, while reserving the breath of the left lung for the time being. The final purpose is to treat both lungs at the same time. Process 3 can only be used only after process 4. Test it with animal lung, before applying it on human. It must be noted that the test with animal lung is intended to prove that it applies to process 3, the human body treatment. The advantage of the reverse sequence is time saving.

a. **Surface treatment clinic (must be professional anesthetist except for bio-chemical test of body energy):** (Fig. [4]5)

b. **Surface treatment clinic scheme diagram:** (Fig. 6)

[4]5. Test with animal lung

Test with animal lung includes two stages: test with one lung of the baby pig and test with both lungs. This process simulates process 3, as specified below:

a. Inject pure PFC into three without virus influence of baby pig:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									

b. Inject 12.6mg/L PFC into three virus-free pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

c. Inject 25.2mg/L PFC into three virus-free pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

d. Inject 12.6mg/L PFC into three infected of baby pig to test its reaction to high-density ozone:

Baby pig	Pure PFC injection 10 mins			Pure PFC injection 30 mins			Pure PFC injection 120 mins		
	Change of blood oxygen amount	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**	**Change of blood oxygen amount**	**Heart pulses**	**Symptom description**
1									
2									
3									

Note 1. The above a-c tests are intended to test whether PEC solvent with or without ozone has bad effect on the lungs. In test c, the density of ozone can be further increased until a reliable pig lung reaction curve, which may serve as a reference for chemists for preparing prescriptions for human treatment.

Note 2. Test d is intended for SARS inflammation, needing an infected pig. Tests with difference densities can be worked out by analogy, but the baby pig under the test is much more resistant to diseases than man. Usually, after 1-3 medicine reaction tests, similar results can be obtained in the tests with various dosages and can be observed under a microscope, and the bio-chemical lab can work out a guided report for the chemists in a short time. The test planning is for your reference only.

6. Important points in designing the operation table

The operation table should be designed such that it can turn horizontally so that the patient on the table can turn left or right with an angle of at least 45 degrees to facilitate the treatment of the left and right lungs.

V. Conclusion

From the viewpoints mentioned above, the ability of ozone to kill virus was recognized worldwide, ozone application in the PFC solvent was confirmed by 1 of remark of the famous production businesses, the PFC solvent used in the lung had also supported by 2-8 of remark of medical document. Therefore, combining the PFC solution and ozone together will attack the SARS virus in no time. The[method] medicine scheme will definitely treat the SARS virus infection and there will be no side effect at all. This invention will save many lives and change medical-history for lung Infection-Disease.

The handling effect of difference in temperature of invention's theory can also kill dead cancer-cell under completely no side effect, the effect of medical treatment cannot compared with Electrotherapy and Chemotherapy, hence the invention bring Gospel for cancer patient, it was so far the brand-new medical concept and brand-new medical method of "Frozen-Therapy".

-end-

Remark of Paper/WebPages:

1. http://cms.3m.com/cms/US/en/2-68/iFcFiFM/view.jhtml
2. http://www.vghtpe.gov.tw/~clinmed/ (89 年 12 月期) [Chinese]

Paper in international journals:

3. Jeng MJ, Kou YR*, Sheu CC, Hwang B. Effects of Exogenous Surfactant Supplementation and Partial Liquid Ventilation on Acute Lung Injury Induced by Wood Smoke Inhalation in Newborn Piglets. Crit Care Med 2003; 31:1166-1174
4. Jeng MJ*, Yang SS, Wolfson MR, Shaffer TH. Perfluorochemical (PFC) Combinations for Acute Lung Injury: An in Vitro and in Vivo Study in Juvenile Rabbits. Pediatr Res 2003;53:81-88.
5. Jeng MJ*, Oliver R, Wolfson MR, Shaffer TH. Partial liquid ventilation: effect of initial dose and redosing strategy in acute lung injury. Pediatr Crit Care Med 2002;3:163-171.
6. Jeng MJ*, Kou YR, Sheu CC, Hwang B. Effects of partial liquid ventilation with FC-77 on acute lung injury in newborn piglets. Pediatr Pulmonol 2002; 33:12-21.
7. Jeng MJ*, Trevisanuto D, Weis CM, Fox WW, Wolfson MR, Shaffer TH. The role of ventilation strategy on Perfluorochemical (PFC) evaporation from the lungs. J Appl Physiol 2001; 90: 1365-1372.
8. Trevisanuto D, Jeng MJ*, Weis CM, Fox WW, Wolfson MR, Shaffer TH. Positive end-expiratory pressure modulates perfluorochemical evaporation from the lungs. Biol Neonate 2003;84:53-58.

(SUBSTITUTE CLAIMS)

Surface Treatment of SARS-Infected Lungs

Amendment on Jan. 02, 2006

Claims of 10/469,063

1. In the lungs infected disease field, wherein said the main characteristic treatment of the Surface Treatment of SARS–Infected Lungs is to inject sterilizing liquid into the lung lobes.

2. The Surface Treatment of SARS–Infected Lungs in claim1, the claim of patent medicine which formal name for the medicine of constituents sterilizing liquid is Fluoro Chemicals (PFCs) adding ozone forming.

3. The Surface Treatment of SARS–Infected Lungs in claim 1, wherein said including any other lung diseases and SARS inflammation.

4. The Surface Treatment of SARS–Infected Lungs in claim 2, wherein said to add the substitutes such the antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.

5. In the claim 2, wherein said the liquid includes all liquids of fluorine element.

6. In the claim 2, wherein said includes any substitute liquid to mixing ozone or the single atom oxygen is decompose by other element.

7. The Surface Treatment of SARS–Infected Lungs in claim 7, wherein said to include a brand-new medical theory that is the Handling Effect Of Difference In Temperature” for cure cancer.

8. In the claim 7, wherein said to include a brand-new method of medical treatment of Frozen-Therapy for kill dead the cancer-cell.

Marked-up the amend claims

Surface Treatment of SARS-Infected Lungs

US Application No. 10/469,063

Claims

1. In the lungs infected disease field, wherein said the main characteristic treatment of the Surface Treatment of SARS–Infected Lungs is to inject sterilizing liquid into the lung lobes.

2. The Surface Treatment of SARS–Infected Lungs in claim1, the claim of patent medicine which formal name for the medicine of constituents sterilizing liquid is Fluoro Chemicals (PFCs) adding ozone forming [a medicine].

3. The Surface Treatment of SARS–Infected Lungs in claim 1, wherein said including any other lung diseases and SARS inflammation.

4. The Surface Treatment of SARS–Infected Lungs in claim 2, wherein said to add the substitutes such the antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.

5. In the claim 2, wherein said the liquid includes all liquids of fluorine element.

6. In the claim 2, wherein said includes any substitute liquid to mixing ozone or the single atom oxygen is decompose by other element.

7. The Surface Treatment of SARS–Infected Lungs in claim 7, wherein said to include a brand-new medical theory that is the Handling Effect Of Difference In Temperature” for cure cancer.

8. In the claim 7, wherein said to include a brand-new method of medical treatment of Frozen-Therapy for kill dead the cancer-cell.

(SUBSTITUTE ABSTRACT)

Surface Treatment of SARS-Infected Lungs

Amendment on Jan. 02, 2006

Invent Abstract

SARS infection has wreaks havoc in China, Hong Kong and Taiwan and its effects sending repercussion throughout the entire international society. The death rate has been high and the Chinese and western medical social were quite helpless about this. For more than hundreds of years, lung infectious diseases have always been classified under medical science as internal organs disease. However, today, this paper will point out that this opinion has been misunderstood. There is a need to associate such infection disease with air as an interface. Therefore, SARS infection is a kind surface ulcerous infection. Since there have been changes from the above-mentioned medical science opinion, we have found the best medical scheme. It will no longer be a dream for SARS infected patients to be discharge from the hospital in a matter of hours. The SARS infected will no longer be life threatening again. Hence, mankind can proudly declare their triumph over SARS. "Surface Treatment infected of SARS infected lungs" is under the brand new medical concept of the outcome. The " 0_1 Therapy" is the core of the "Surface Treatment". The sterilizing liquid_that is infected into the lung lobes is the surface treatment liquid for 0_1 therapy of the lungs. The formal name for this liquid is Per Fluoro Chemical (PFCs) and the sterilizing is ozone.

Abstract Pictures

(Fig.5)



(Marked-up ABSTRACT)

Surface Treatment of SARS-Infected Lungs

Invent Abstract

SARS infection has wreaks havoc in China, Hong Kong and Taiwan and its effects sending repercussion throughout the entire international society. The death rate has been high and the Chinese and western medical social were quite helpless about this. For more than hundreds of years, lung infectious diseases have always been classified under medical science as internal organs disease. However, today, this paper will point out that this opinion has been misunderstood. There is a need to associate such infection disease with air as an interface. Therefore, SARS infection is a kind surface ulcerous infection. [ ] Since there have been changes from the above-mentioned medical science opinion, we have found the best medical scheme. It will no longer be a dream for SARS infected patients to be discharge from the hospital in a matter of hours. The SARS infected will no longer be life threatening again. Hence, mankind can proudly declare their triumph over SARS. [ ] "Surface Treatment infected of SARS infected lungs" is under the brand new medical concept of the outcome. The " 0_1 Therapy" is the core of the "Surface Treatment". The sterilizing liquid that is infected into the lung lobes is the surface treatment liquid for 0_1 therapy of the lungs. The formal name for this liquid is Per Fluoro Chemical (PFCs) and the sterilizing is ozone.

Abstract Pictures

(Fig. [4] 5)



Amendment of the Claims Before the International Bureau

Basis Article 19 / 34

Authorized officer: S.Mandallaz

In the International Bureau of WIPO

Applicant(s)	:	Lin Zhen-man	)
Application No.		PCT/SG03/00145	) Amendment
Filed	:	12 June 2003	)
For	:	**Surface Treatment of SARS–Infected Lungs**	))

Amendment by inventor

Patent Cooperation Treaty
International Bureau of Wipo
34 Chemin Des Colombettes
1211 GENEVA 20 SWITZERLAND

E-mail: publicinf@wipo.int
Tel: 41 22 338 9661
Fax: 41 22 338 7140

Authorized officer:

Because the medicine and methods of medical treatment had to coexist or ambiguous in my claims of invention patent possibility that in view by the search authority of Austrian Patent Office, and therefore the search authority was refused given a report include the subject of search for the medicine in my claims.

The search authority of Austrian Patent Office had power to refused search for medical method basis the Rule 39. 1 (IV), but the Austrian Patent Office cannot to refused search for a medicine of sterilizing liquid and inventor's complains was nobody to understand! Applicant begs Austrian Patent Office must to complete the responsibility under PCT legal stipulation.

Therefore, inventor basis on the Article 19 of PCT law to change the claims, the amendment claims are divide for two different editions that:

1. The "Claim A" are used for to only allow the medicine patent by patent-law of country;
2. The "Claim B"are used for the inclusion of the medicine and methods of medical treatment allow the medicine patent by patent-law of country, for instance US patent office and so on.

The Claims of original is below:

1. The main characteristic of the "Surface Treatment of SARS–Infected Lungs" is to inject sterilizing liquid into the lung lobes.
2. The formal name for the medicine of sterilizing liquid is Per Fluoro Chemicals (PFC) adding ozone forming a medicine.
3. Including any other lung diseases and SARS inflammation.
4. To add antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.

The amendment of "Claim A" is below:

1. The liquid medicine name of "Surface Treatment of SARS–Infected Lungs" is Per Fluoro Chemicals (PFC) mixing ozone forming a medicine.
2. In the claim 1, the liquid includes all liquids of fluorine element.
3. In the claim 1, includes any substitute liquid to mixing ozone or the single oxygen is decompose by other element.
4. In the Claim 1 of liquid medicines include the option of mixing any chemical that might kill or restrain the germs, for instance any antibiotics or other bactericide and so on.
5. In the Claim 1, includes any other lung diseases and SARS inflammation.

Obvious, the subject of Claim is liquid medicine does not change.

The amendment "Claim B" is below:

1. The main characteristic of the "Surface Treatment of SARS–Infected Lungs" is to inject sterilizing liquid into the lung lobes.
2. "Surface Treatment of SARS–Infected Lungs" in claim1, the formal name for the medicine of sterilizing liquid is Fluoro Chemicals (PFC) adding ozone forming a medicine.
3. "Surface Treatment of SARS–Infected Lungs" in claim1, including any other lung diseases and SARS inflammation.
4. "Surface Treatment of SARS–Infected Lungs" in claim1, to add antibiotics or other bactericide into the sterilizing liquid to suppress or to kill the virus.
5. In the claim 1, the liquid includes all liquids of fluorine element.
6. In the claim 1, includes any substitute liquid to mixing ozone or the single oxygen is decompose by other element.
7. The claims include a brand-new medical theories that is "The handling effect of difference in temperature" for cure cancer.
8. The claims include a brand-new methods of medical treatment of "Frozen-Therapy" for kill dead the cancer-cell.

The subject of Claims was annexed brand-new medical theories of claim 6 and methods of medical treatment of claim 7. They are stated in the specification and relate to the original claim 1, because, inventor has the power to add in the claims.

The amendment is further adds on the describe of PFC and insert the part of "Selection of PFC solvent" of specification, that is below:

【Per fluorine chemical compound (Per fluoro chemicals, PFC) in the innovation medicine application of this case is an important liquid-medium of oxygen for separate out single oxygen-atom. The member-type of PFC are **C(5-18)F(12-38),** the length of chain of member structure was shown at the number of C, the number of C decides was inner physical special quality, so the Boiling-Point was at **30℃-215℃.** That is to say, the Boiling-Point temperature with the number of C is in proportion. This application seeks to first recommend **C6F14 or C7F16,** its purpose for volatilizes as soon as possible then pouring into the lung after destroys the germs. But in actual practice of clinical option, more considerations will have to be taken into account, for instance, the level of ulcer by the germs influence and the density of single oxygen-atom and so on; however, then the other fluorine chemical compounds such as C5F9H3O while offering swim-dissociating for the liquid medium of single oxygen-atom, which must emphasize the density effect of single oxygen-atom Depletion Potential.】

Please see the part IIII. (1) of the specification, above-mentioned additions had shown to add the base line. Obviously, the addition of the above-mentioned does not affect the novel of invention.

The amendment has further added a new figure to expose the art. of mixing PFC and ozone, according to order it was designate to be Fig.4, the described of Fig.4 insert for part IIII (3) and that under line shown in the **MARKED-UP** SUBSTIUTE SPECIFICATION, that below:

【The working process-method of mixing of PFC and ozone are shown in Fig.4. Fig.4-1 is shown the o zone supply；Fig.4-2 is shown the O3 Contriver；Fig.4-3 is shown PFC supply；Fig.4-4 is shown the passageway valve of liquid； Fig.4-5 is shown the pump of gas and liquid mixing；Fig.4-6 is the mix vessel； Fig.4-7 is the digital type tester of ozone density and have the export-ability to brake of the working of the mixing pump；Fig.4-8 is the controller of altitude of liquid and have the export-ability to the working of the passageway

valve of liquid.】

Obviously, the addition of the above-mentioned does not affect the novel of invention; it is the responsibility of inventor to expose application-technology more distinctly. Therefore, the original Fig.4 according to order was designated to be Fig.5.

The " b. Surface treatment clinic scheme diagram" of part IIII. (3) of the original copy was deleted and turn in accordance to order it was designated to be Fig.6, this kind of change is reasonable and necessary. Obviously, the changes to the above-mentioned do not affect the novel of invention.

The amendment included such as the correction on the usage of wrong words and so on, the accustomed to the amendment was underlined to show the correct ones; the deleted parts were represented by the square brackets.

In the conclusion, the inventor had increased to state also all above-mentioned that such amendments might have on the description and the drawings.

Applicant basis of Article 19 of PCT law to amend the claims of the international application by filing amendments with the International Bureau within the prescribed time limit. For the foregoing reasons, it is respectfully submitted that the application is now in condition for allowance.

For the foregoing reasons, it is respectfully submitted that the application is now in condition for allowance.

Respectfully submitted,

Dec.12, 2003

Amendment by Applicant

SG ID S2665604D
Application address:
10 Ava Road Ava Tower
 # 19-07 329949
Singapore
Tel: 65 63533647 Fax: 65 6258563
lzmyc@singnet.com.sg

Protesting for WTO conference in HK

Attach-Filed-c

Dec.16, 2005

Per trading minister of WTO/WHO
Dear
Sirs/Madam

The fair trade and intellectual property are WTO's principles and the important vital of society civilization with extend by standard of the human rights. Therefore, the WTO has the duty to norm and investigate the morality, behavior of any member countries.

At present, at the location of WTO conference, if the WTO have not look into the unfair deal of HK Government towards Lin Zhen Man (lzm) of a HK citizen and unceasingly to deceived to tease for all HK citizens that ***Tamiflu*** it could cure bird flu for this reason to tort (use in not public) lzm 's invention to cure the SARS and bird flu, at the same time to persist in murder for lzm, the WTO conference at this state for conference, didn't the WTO not feels shameful?

The WTO must follow with interest the HK Gov. to deprive of the civil rights on the cases of LDBM 220/2005, FAMV 16/2004, FAMV 21/2002 and FAMV 1/2002 etc and not to value intellectual property and simultaneously for concealing lzm's invention to cure the SARS and bird flu!

The China, HK Gov. did not thank lzm's invention that saved over one thousand China and Hong Kong person after on May.15, 2003, but the China and Hong Kong Government did not thank the lzm of inventor, the Donald TSANG Yam-kuen of HK Chief Executive who was to continued holding thus below the 500W power antenna of mobile phone at short range to aim and murder the Lin Zhen Man (lzm)! (http://www.ycec.com which have detailed explain!)

Radiation 270 multiples for over the standard! The evidence of murder below!

(http://www.ycec.com/LDBM-48-D18.pdf)

The WTO/WHO must to follow with interest the HK Gov. was to become an uncivilized!

The trading minister of each country, please pass on to your Government, the lzm's medical invention which was into the Patent Office of your country now, the ***Tamiflu*** is not effective in curing the bird flu, the UN in the middle to harmony with the lie which is not intolerable!

If you are a civilization and rule by law of country, please don't assist; endure the China, HK Gov. to conceal! Or else, your country should be to it same the China, HK Gov. to furtively to use lzm's medical invention and get an accusation of no to value the intellectual property, still in important, **to deceive as will as your country people**!

Lin Zhen-man

Hong Kong Dec. 16, 2005

(to connect with the behind page)

Attach-Filed-d

LZM's warning to member countries of WTO/WHO

Per trading minister of WTO/WHO member
Dear
Sirs/Madam

To expose conceal for medical science invent!

Using air as an interface definition, the bird flu, like SARS and other types of flu infections, is a superficial bacterial infection of the lungs. Such bacterial infections can only be dealt with superficially. This can be said to be the law of the conversation of energy. And according to the law of the conversation of energy, any medicine which is to be ingested into the stomach or injected cannot be considered as a specific medicine, in the context of superficial bacterial infections.

To explain further, the *Tarniflu* relies on absorption through the intestines and stomach in order to enter the blood stream to produce antibodies and to neutralize the viruses produced by the bacteria infection, Obviously, neutralization of the virus and killing of the bacteria are two totally different matters.

While the vaccine can certainly bring about the production of antibodies in the blood, and neutralization of viruses is indeed the specialty of *Tamiflu*, the effect of *Tamiflu* really depends on the type of the bacteria which produced the virus in the first place! Yet the China and HongKong governments have been conducting intensive propaganda campaigns emphasizing the neutraIization of viruses by *Tamiflu* and the specialty of *Tamifiu*, with no explanation as to how to kill the bacteria. This clearly demonstrates an ignorance of medical science and an effort to deliberately conceal the truth!

Therefore, the *Tamifiu* will not be able to kill the bird flu and SARS bacteria. The China and Hongkong governments are jointly deceiving the people! In actual fact, the China and Hongkong governments have been using LZM's invention secretly to cure SARS and bird flu patients since 15 May 2003. However, their inability to publicly use the invention has resulted in the deaths of many from SARS and bird flu. This has also resulted in many phthisis patients not being able to benefit from the invention of the PFCO medicine! Such is the sorrowful state of the Hongkong society!

The China and Hongkong governments should respond to LZM's criticism! LZM's patent application of PCT/SG03/00145 has now been submitted to the relevant patent authorities of 80% of WTO/WHO countries, any government's policy of medical treatment and to renew the textbook which can't do without this invent, therefore, please do not assist in concealing the truth, in insulting civilization, falsifying medical science, and deceiving the people of your country, thereby leaving a bad name in history.

Please be concerned with the civil rights of Hong Kong and to look through the website http://www.ycec.com/Lt-to-world-051017.htm and remind your government to stop concealing the invention of curing SARS and bird flu!

I hope that per member country of WTO/WHO can have the full control over the bird flu in your country.

Lin Zhen-man



Hong Kong
Dec. 16, 2005

(to connect with the behind page)

LZM Patent Office

10 Ava Road Ava Tower # 19-07 Singapore 329949 (http://www.ycec.com)
Tel: 65 63533647 Fax: 65 62585636 Email: lzmyc@singnet.com.sg

Untied States Patent and Trademark Office
Art Unit 3644 Examiner
Tel: 1 703 306 4159
Fax: 1 703 306 4195
Date: Jan. 14, 2004

Re: US Patent Application No. **10/029,951**
in the name of Zhen-Man Lin
Claiming priority from Chinese Patent
Application Filing date: 12/31/2001

Dear
Mr. Charles Jordan,

I had send the defense document in **responds to the Office Action by** registration mail **on** Nov. 28, 2003. The documents are found in my websites now and the subject titles are as below:

	Subject Document joined	Date	http://www.ycec.com /…add…htm Web page joined
1	Letter to examiner's supervisor	**Nov.28,03**	Letter_to_request-281103.htm
2	Letter to Mr. Dinh of Examiner	**Oct.27, 03**	Letter_to_question-271003.htm
3	Second Detailed Action by Examiner	**Jun.25, 03**	www.ycec.com/us-office-250603.tif
4	Amendment by inventor	**Nov. 28, 03**	Amendment-E-281103.htm
5	New-SPECIFICATION	**Nov. 28, 03**	New-SPECIFICATION-281103.htm
	CLAIM CHANGES		(For instance Fig1-6.htm) www.ycec.com/New-Fig1.htm
	News figure:	**Nov. 28, 03**	Fig1. Fig.2 Fig.3 Fig.4 Fig.5 Fig.6
6	ShenZhen Agent Letter to Mr. Dinh of Examiner originally-Fig.1 & Fig.4	**July15, 03**	SZ-agent-letter-150703.htm originally-Fig.1 & Fig.4
7	CN1408608A Figure 1-5	**Apr09, 03**	CN1408608A-090403.htm

But I had in your websites of **http://pair.uspto.gov/cgi-bin/final/pairsearch.pl** and I found that they are wrong:

File Contents History		
Number	**Date**	**Contents Description**
30	**01-07-2004**	**Mail Abandonment for Failure to Respond to Office Action**
29	**01-06-2004**	**Abandonment for Failure to Respond to Office Action**
28	**06-20-2003**	**Mail Final Rejection (PTOL - 326)**
27	**06-16-2003**	**Final Rejection**

I did not **abandonment for Failure to Respond to Office Action**, so why did you cancel my application? If there was the mistake of postal delivery, please allow me to send again, please does not cancel my application right.

Thank you for your Kind attention and please reply to me as soon as possible.

Sincerely yours,

Applicant : Lin Zhen Man
10 Ava Road, Ava Tower, # 19-07
Singapore 329949

Jan. 14, 2004

YET CHONG ELECTRIC COMPANY

BLK C-4, 13/F., WING HING IND.BLDG., 14 HING YIP ST., KWUN TONG, KLN, H.K.
TEL : (852) 23440137 FAX : (852) 23419016
Home page: www.ycec.com Email: lzm@ycec.com

Untied States Patent and Trademark Office
Art Unit 3644 Examiner
Tel: 1 703 306 4159
Fax: 1 703 306 4195
Date: Feb. 04, 2004

Re: US Patent Application No. **10/029,951**
in the name of Zhen-Man Lin
Claiming priority from Chinese Patent
Application Filing date: 12/31/2001

Dear
Mr. Dinh, Tien Quang

I had send the defense document in responds to the Office Action by registration mail on Dec. 02, 2003. The Certificate of Posting of a Registration Packet is below:

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of a Registered Packet

寄往 Addressed to
姓名 Name United States
城市 City Patent & Trademark Office
國家 Country U.S.A.
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 61233445 8
日戳 Date Stamp
郵務員簽名 Signature of accepting officer

Post office confirms again

The item was sent on 2. 12. 2002. from HK

I did not **abandonment for Failure to Respond to Office Action**, If there was the mistake of postal delivery, please allow me to send again, **please filed in my application.**

Thank you!

Sincerely yours,

Applicant :
Lin Zhen Man
BLK C-4, 13/F., WING HING IND.BLDG., 14
HING YIP ST., KWUN TONG, KLN, H.K.
Feb. 04, 2004

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of a Registered Packet

寄往 Addressed to
姓名 Name United States
城市 City Patent & Trademark Office
國家 Country U.S.A.
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 61233445 8
日戳 Date Stamp
郵務員簽名 Signature of accepting officer

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of Registered Packet

寄往 Addressed to
姓名 Name Dinh, Tien Quang
城市 City U.S. Patent & Trademark office
國家 Country D.C 20231 U.S.A
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 838 697 343
日戳 Date Stamp 9 2 04 KEA
郵務員簽名 Signature of accepting Officer

YET CHONG ELECTRIC COMPANY

BLK C-4, 13/F., WING HING IND.BLDG., 14 HING YIP ST., KWUN TONG, KLN, H.K.
TEL : (852) 23440137 FAX : (852) 23419016
Home page: www.ycec.com Email: lzm@ycec.com

Untied States Patent and Trademark Office
Art Unit 3644 Examiner
Tel: 1 703 306 4159
Fax: 1 703 306 4195

Re: US Patent Application No. **10/029,951** in the name of Zhen-Man Lin
Claiming priority from Chinese Patent
Application Filing date: 12/31/2001

Dear
Mr. Charles Jordan,

I am very much regretted that I brought up again my letter to you on Jan. 14, 2004.

In the letter I had emphasized that I had send the defense document in **responds to the Office Action by** registration mail, now having the result send by the postal-tracing to you, the attach 1 shown an information by mail Tracing office of Hong Kong post, the attach 2 shown that my registration mail was received by US patent office that verified from US Post on Feb.24, 2004.

I had send again the defense document in **responds to the Office Action by** registration mail on Feb.09, 2004.

The American government do not change the principle of Human Rights with rule by law that because by the Former Chinese government leader was to do every evil against me! Please peruse to attach 3, the letter was send to Bush president about my complain on Nov.28, 2003.

Same the matter appeared in my another invention application in US patent office, the application number 10/469063 and the date was July.29, 2003, but the application had been to put on one side up to now, please peruse to attach 4, the attitude of American government can be relation the public justice of international social !

The same the matter appeared in my another invention application in US patent office, the application number 10/469063 and the date was July.29, 2003, but the application had been to put on one side up to now, please peruse to attach 4-7, the attitude of American government can be relation the public justice of international social !

Hope to hear from you soon!

Yours faithfully,

applicant: Lin Zhen Man
Mar. 26, 2004

Yet Chong Electric Company
Blk C-4, 13/F., Wing Hing Ind. Bldg., 14 Hing Yip St.,
Kwun Tong, Kln, H.K.
lzmyc@ycec.com & ycec@163.net

10/469063 Applicant address
10 Ava Road Ava Tower # 19-07
Singapore 329949
lzmyc@ycec.com & ycec@163.net

The attach documents

attach 1	**mail Tracing office of Hong Kong post**	**http://www.ycec.com/HK-post-030304.htm**
attach 2	verified from US Post	**http://www.ycec.com/US-post-091203.htm**
attach 3	**letter to Bush president**	**www.ycec.com/LT-to-Bush-President-281103.htm**
attach 4	**letter to PCT**	**www.ycec.com/To-IB-Mr.Francis-090304.htm**
attach 5	**letter to Dr. Julie L. Gerberding**	**www.ycec.com/LT-Dr-Gerberding-031103.htm**
attach 6	**letter to Dr. Julie L. Gerberding**	**www.ycec.com/LT-Dr-Gerberding-211203.htm**
attach 7	**Request 10/469063 Filing Receipt**	**www.ycec.com/request-Filing-Receipt.htm**

attach 1

Hongkong Post
香港郵政

來函檔號 Your ref.:
本署檔號 Our ref.: 04032577E
電話 Tel: 2921 2211
傳真 Fax: 2543 0469

香港中環統一碼頭道 38 號
海港政府大樓一樓
香港郵政郵件查詢組
網址：www.hongkongpost.com

Hongkong Post Mail Tracing Office
1/F, Harbour Building
38 Pier Road, Central
Hong Kong
Website: www.hongkongpost.com

03 Mar 2004

Lin Zhen Man
Blk C-4, 13/F, Wing Hing Ind. Bldg.,
12-14 Hing Yip Street, Kwun Tong,
Kowloon, Hong Kong.

Dear Sir / Madam,

We refer to your enquiry dated 21 Feb 2004 concerning the Outward Registered Letter with item no. RR612334458HK sent to United States Patent and Trademark Office on 02 Dec 2003.

The U.S.A. Post Office advised that the item was delivered on 9 Dec 2003 .

If you require any further information, please feel free to call us at 2921 2211.

Yours faithfully,

Ho Kam Wah
(K.W. HO)
for Manager (Mail Tracing Office)

attach 2

mto@hkpo.gov.hk Fax: 2341 9016 Mr. Lam

寄件者: "USPS_Track_&_Confirm_" <USPS_Track_Confirm@usps.com>
收件者: <mto@hkpo.gov.hk>
傳送日期: 2004年2月24日 16:37
主旨: USPS Shipment Info for RR61 2334 458H K

This is a post-only message. Please do not respond.

04032577E has requested that you receive the current Track & Confirm information, as shown below.

Current Track & Confirm Info provided by the U.S. Postal Service, 02/24/04

Label Number: RR61 2334 458H K

Service Type: Registered

Shipment Activity	Location	Date & Time
DELIVERED	WASHINGTON DC 20231	12/09/03 7:46am
ARRIVAL AT UNIT	WASHINGTON DC 20074	12/08/03 5:44am

USPS has not verified the validity of any email addresses submitted via its online Track & Confirm tool.

For more information, or if you have additional questions on Track & Confirm services and features, please visit the Frequently Asked Questions (FAQs) section of our Track & Confirm site at http://www.usps.com/shipping/trackandconfirmfaqs.htm

YET CHONG ELECTRIC COMPANY

BLK C-4, 13/F., WING HING IND.BLDG., 14 HING YIP ST., KWUN TONG, KLN, H.K.
TEL : (852) 23440137 FAX : (852) 23419016
Home page: www.ycec.com Email: lzm@ycec.com

Untied States Patent and Trademark Office
Art Unit 3644 Examiner
Tel: 1 703 306 4159
Fax: 1 703 306 4195
Date: Feb. 04, 2004

Re: US Patent Application No. **10/029,951**
in the name of Zhen-Man Lin
Claiming priority from Chinese Patent
Application Filing date: 12/31/2001

Dear
Mr. Dinh, Tien Quang

I had send the defense document in responds to the Office Action by registration mail on Dec. 02, 2003. The Certificate of Posting of a Registration Packet is below:

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of a Registered Packet

寄往 Addressed to 姓名 Name: United States
城市 City: Patent & Trademark Office
國家 Country: U.S.A.
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 61233445 8
日戳 Date Stamp
郵務員簽名 Signature of accepting officer

Post office confirms again
The item was sent on 2. 12. 2002. from HK

I did not **abandonment for Failure to Respond to Office Action**, If there was the mistake of postal delivery, please allow me to send again, **please filed in my application.**

Thank you!

Sincerely yours,

Applicant :
Lin Zhen Man
BLK C-4, 13/F., WING HING IND.BLDG., 14
HING YIP ST., KWUN TONG, KLN, H.K.
Feb. 04, 2004

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of a Registered Packet

寄往 Addressed to 姓名 Name: United States
城市 City: Patent & Trademark Office
國家 Country: U.S.A.
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 61233445 8
日戳 Date Stamp
郵務員簽名 Signature of accepting officer

Hongkong Post 香港郵政 投寄掛號郵件證明書 Certificate of Posting of Registered Packet

寄往 Addressed to 姓名 Name: Dinh, Tien Quang
城市 City: U.S. Patent & Trademark office
國家 Country: D.C 20231 U.S.A
空郵 Air ✓ | 平郵 Surface | 快郵 Express | 派遞通知書 Advice of Delivery
掛號郵件編號 Regn. No. 828 687 343
日戳 Date Stamp: 9 2 04
郵務員簽名 Signature of accepting Officer